Trump Media to Raise $2.5 Billion for Bitcoin Treasury
Trump Media & Technology Group (TMTG) said on Tuesday that institutional investors will purchase $2.5 billion in the company's stock, with the proceeds going toward a bitcoin reserve.
The deal comprises $1.5 billion in common stock and another $1 billion in convertible notes priced at a 35 percent premium, according to a
Bitcoin will be held on TMTG's balance sheet alongside existing cash, cash equivalents, and short-term investments totaling $759 million as of the end of the first quarter of 2025, according to the statement.
TMTG said it has subscription agreements with approximately 50 institutional investors and that the proceeds have been earmarked for the creation of a 'Bitcoin treasury.'
Crypto platforms Anchorage Digital and Crypto.com will provide custody for the treasury, the company said.
Along with social media platform Truth Social and the streaming platform Truth+, TMTG also operates financial services platform Truth.Fi.
Related Stories
5/1/2025
3/26/2025
In March, TMTG
'We view Bitcoin as an apex instrument of financial freedom, and now Trump Media will hold cryptocurrency as a crucial part of our assets,' TMTG CEO and Chairman Devin Nunes said in Tuesday's statement.
The former congressman said the investment will help defend the company against 'harassment and discrimination by financial institutions,' behavior he said plagues 'many Americans and U.S. firms.'
The investment will 'create synergies for subscription payments, a utility token, and other planned transactions across Truth Social and Truth+,' Nunes said. 'It's a big step forward in the Company's plans to evolve into a holding company by acquiring additional profit-generating, crown jewel assets consistent with America First principles.'
Shares of the company were up by 2.47 percent as of early Wednesday morning but have declined by more than 53 percent over the past 12 months.
Trump Admin Touts Digital Assets
The announcement comes as the Trump administration continues to embrace digital assets, which Trump widely touted throughout his 2024 election campaign. In 2019, however, he
In January, Trump signed an
The group will comprise several senior officials, including the secretary of the treasury and the secretary of homeland security, and will be chaired by David Sacks, the White House's special adviser for artificial intelligence and crypto, according to the order.
It will be tasked with proposing a 'federal regulatory framework governing the issuance and operation of digital assets, including stablecoins,' the order stated.
Trump's order said that the digital asset industry 'plays a crucial role in innovation and economic development in the United States, as well as our Nation's international leadership.'
In March, Trump also
That announcement prompted pushback from Sen. Elizabeth Warren (D-Mass.), who said it 'triggered a surge in crypto prices before a sharp drop, raising concerns about possible market manipulation and insider trading.'
In a March
In April, Warren also
'All SEC decisions and actions involving TMTG and President Trump's financial interests should be carefully managed to ensure that they are free from undue political interference and influence from the President and his administration,' Warren said.
The Epoch Times contacted the White House for comment but did not receive a response by publication time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Hamas responds to US plan for Gaza ceasefire, says proposal aimed at ‘permanent ceasefire'
Hamas says that it has responded to a ceasefire plan put forward by President Trump's envoy on Gaza, but did not make clear what its exact response was. In a statement Saturday, Hamas said that its 'proposal' to the mediators – Qatar and Egypt — 'aims to achieve a permanent ceasefire, a comprehensive withdrawal from the Gaza Strip, and ensure the flow of aid to our people and our families in the Gaza Strip.' 'As part of this agreement, ten living Israeli prisoners held by the resistance will be released, in addition to the return of eighteen bodies, in exchange for an agreed-upon number of Palestinian prisoners,' the statement said. The US-backed and Israel-approved proposal seen by CNN on Friday includes Hamas releasing 10 Israeli hostages and 18 deceased hostages in exchange for 125 Palestinian prisoners serving life sentences and 1,111 Gazans detained since the war began. Negotiations toward a permanent ceasefire would begin immediately on the first day of the 60-day truce, according to the proposal. The terms of the agreement would also allow humanitarian aid to enter Gaza 'immediately' and be distributed 'through agreed upon channels,' including the United Nations and the Red Crescent, according to the proposal. But the draft agreement contained no intrinsic guarantee of a permanent end to the war, a key Hamas demand, nor assurances that the ceasefire will be extended as long as negotiations continue. Instead, it said that US President Donald Trump is 'committed to working to ensure that good faith negotiations continue until a final agreement is reached.' Hamas had initially signaled reluctance to accept the terms of the deal. Bassem Naim, a member of the Hamas political bureau, said on Facebook Thursday that the framework did 'not respond to any of our people's demands' but that discussions were underway, nonetheless. This is a developing story and will be updated. CNN's Dana Karni, Alex Marquardt, Kylie Atwood, Jeremy Diamond and Oren Liebermann contributed to this report.
Business Insider
44 minutes ago
- Business Insider
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy' Stocks
After a rocky start to the spring, Wall Street came roaring back in May. President Trump's softened tariff stance reignited demand for risk assets, triggering the market's biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Confident Investing Starts Here: Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. 'The effects of the stock market rally from the lows seen on April 8 appear to us to augur positively for investors practicing diversification and patience notwithstanding near-term uncertainties… We remain overweight US equities and do not ascribe to the view that US exceptionalism is fading,' Stoltzfus noted. Against this backdrop, Oppenheimer analyst Jay Olson has picked out his winners for the months ahead, zeroing in on two stocks in particular – including one with the potential to jump ~550% by this time next year. We checked in with the TipRanks database to see how the rest of Wall Street views these names. The verdict? Both picks carry Strong Buy consensus ratings across the board, with substantial upside potential. Let's take a closer look at the details. Voyager Therapeutics (VYGR) One company Oppenheimer is especially bullish on is Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer's disease and Friedreich's ataxia – both of which have limited therapeutic options. Voyager's lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer's disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer's research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure. Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer's. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026. The promise of Voyager's TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich's ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones. Currently trading at $2.74 per share, VYGR may be flying under the radar – but Oppenheimer's Jay Olson sees it as a compelling entry point. 'We remain enthusiastic about VYGR's unique platform and optionality, and believe VYGR is well-positioned to pursue tau-targeting with different approaches. VYGR's strong balance sheet with a cash runway into mid-2027 should offer stability… Additionally, we are encouraged by the positive preclinical data, external validation of the platform technology through multiple collaborations with industry leaders, a strong management team, and our optimistic long-term view on the gene therapy and CNS therapeutic area,' Olson said. To this end, Olson rates VYGR an Outperform (i.e., Buy), and his $18 price target implies room for a stunning 556% upside potential in the next 12 months. (To watch Olson's track record, click here) Tvardi Therapeutics (TVRD) The second name catching Oppenheimer's attention is Tvardi Therapeutics, another biopharmaceutical firm – but a newcomer to the public markets. The TVRD ticker began trading on the NASDAQ on April 16 of this year, following the completion of a merger between Tvardi Therapeutics and Cara Therapeutics. Following its public debut, Tvardi is now focused on developing breakthrough therapies for fibrosis-driven diseases. Its approach centers on targeting STAT3 (signal transducer and activator of transcription 3), a key protein in the STAT family, known for its pivotal role in numerous cellular processes. At the center of Tvardi's clinical efforts is TTI-101, an oral small-molecule STAT3 inhibitor that selectively targets pY-STAT3 within the SH2 domain. Tvardi is advancing TTI-101 as a treatment for both hepatocellular carcinoma (HCC) and idiopathic pulmonary fibrosis (IPF), two diseases marked by high unmet need and limited effective therapies. Early clinical results have been encouraging. In a first-in-human Phase 1 trial involving patients with advanced solid tumors, including HCC, TTI-101 was well tolerated with no dose-limiting toxicities. Pharmacodynamic data confirmed target engagement, with biopsies showing reduced levels of activated STAT3. Tvardi expects topline data from its ongoing Phase 1b/2 REVERT Liver Cancer clinical trial in HCC to be available in the first half of 2026. Meanwhile, building on insights from the same trial, Tvardi is also advancing the REVERT IPF Phase 2 study – a randomized, double-blind, placebo-controlled trial evaluating TTI-101, both as a monotherapy and in combination with nintedanib, in patients diagnosed with IPF within the past seven years. On May 27, 2025, the company announced that enrollment was complete, with topline results expected in the fourth quarter of this year. The potential of TTI-101, based on its earlier clinical trial results and optimistic forecasts for the current trials, has not gone unnoticed by Oppenheimer's Olson. The analyst is encouraged by the possible long-term returns, assuming success in both the trial and regulatory process. 'We see an underappreciated opportunity for lead asset TTI-101 as we forecast ~$1.2B peak risk-adjusted sales in 2040. Blinded Ph2a interim data suggest that TTI-101 could reverse IPF progression, thus supporting favorable differentiation from key competitors, with detailed Ph2a results expected in 2H25 serving as a potential valuable inflection point. In HCC, we believe TTI-101 offers a novel, mechanistically distinct approach, with interim Ph1b/2 data suggesting synergy in combination with SoC ahead of topline results in 1H26. We leverage our expertise in IPF and HCC to inform our analysis, and view TVRD as well-capitalized through key catalysts… Based on our DCF valuation of TVRD, we believe that its shares remain underappreciated,' Olson stated. With that backdrop, Olson rates TVRD an Outperform (i.e., Buy), alongside a $65 price target, suggesting a potential upside of 129% from current levels. Overall, this new stock has picked up 4 analyst reviews since it went public, and all are positive – making the Strong Buy consensus rating unanimous. TVRD is currently trading for $28.34, and its $50.75 average price target suggests that the shares have a 79% upside lying in wait for the year ahead. (See TVRD stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
Oil finishes down on possible OPEC+ output hike
By Erwin Seba HOUSTON (Reuters) -U.S. crude futures fell on Friday as traders expected OPEC+ would decide on Saturday to boost oil output for July beyond previous forecasts. Brent crude futures settled down 25 cents, or 0.39%, at $63.90 a barrel. U.S. West Texas Intermediate crude finished down 15 cents, or 0.25%, at $60.79 a barrel, having earlier dropped more than $1 a barrel. The Brent July futures contract is due to expire on Friday. The more liquid August contract was down 71 cents, or 1.12%, at $62.64 a barrel. At these levels, the front-month benchmark contracts were headed for weekly losses over 1%. Prices dipped into negative territory after Reuters reported that OPEC+ may discuss an increase in July output larger than the 411,000 barrels per day (bpd) rise that the group decided on for May and June. "What OPEC+ is planning doesn't look particularly supportive for the oil market," said Matt Smith, Kpler's lead analyst for the Americas. The potential OPEC+ output hike comes as the global surplus has widened to 2.2 million bpd, likely necessitating a price adjustment to prompt a supply-side response and restore balance, said JPMorgan analysts in a note, adding that they expected prices to remain within the current range before easing into the high $50s by year-end. Phil Flynn, a senior analyst with Price Futures Group, said an online post on Truth Social by U.S. President Donald Trump that seemed to threaten more changes in tariff levels for Chinese imports also put pressure on crude prices. "Trump's Truth Social message on China failing to observe a truce on tariffs also combined with the Reuters headline to push prices down," Flynn said. Trump's tariffs were expected to remain in effect after a federal appeals court temporarily reinstated them on Thursday, reversing a trade court's decision a day earlier to put an immediate block on the sweeping duties. U.S. energy firms this week cut the number of oil and natural gas rigs operating for a fifth week in a row to the lowest since November 2021, energy services firm Baker Hughes said in its closely followed report on Friday. It was the first time since September 2023 that the number of rigs declined for five straight weeks. Baker Hughes said this week's decline put the total count down by 37 rigs, or 6%, from this time last year. Oil rigs fell by four to 461 this week, their lowest since November 2021, the company said. Gas rigs rose by one to 99.
